STOCK TITAN

Millennium Group and Israel Englander file 13G/A disclosing 5.1% stake in Chemours

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Schedule 13G/A for The Chemours Company shows Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported aggregate beneficial ownership of 7,576,095 shares of Chemours common stock, equal to 5.1% of the class. The filing specifies shared voting power of 7,443,038 and shared dispositive power of 7,576,095, and reports sole voting and dispositive powers as 0.

The filing states the reporting persons "ceased to be beneficial owners of more than 5% of the outstanding Common Stock as of July 1, 2025." The amendment is signed August 7, 2025, and includes a Joint Filing Agreement as Exhibit I. No purchase prices, transaction dates, or intent to influence control are disclosed in the document.

Positive

  • Clear quantitative disclosure of aggregate shares (7,576,095) and percentage (5.1%)
  • Amendment and signatures dated August 7, 2025, plus a Joint Filing Agreement (Exhibit I) enhance transparency

Negative

  • Cessation of >5% ownership as of July 1, 2025, indicating the reporting persons no longer meet the >5% threshold
  • No transaction details provided (no purchase/sale dates or prices disclosed in the filing)

Insights

TL;DR: Millennium entities reported a 5.1% position (7,576,095 shares) in Chemours, then ceased to own >5% as of July 1, 2025.

The Schedule 13G/A transparently discloses the aggregate share count and voting/dispositive breakdowns: 7,576,095 shares (5.1%) aggregate, shared voting power 7,443,038, and shared dispositive power 7,576,095. The document is an amendment filed and signed on August 7, 2025, and includes a Joint Filing Agreement. The filing does not include trade prices or specific transaction timing; it functions as regulatory disclosure of ownership levels.

TL;DR: Filing is routine disclosure of ownership limits and signatures; ceasing to exceed 5% changes reporting status under Schedule 13G.

The report indicates sole powers are 0 and that reported rights are shared through managed entities, consistent with holdings controlled by investment management structures. The explicit statement that the reporting persons ceased to be beneficial owners above the 5% threshold as of July 1, 2025 is the material governance detail; Exhibit I documents the parties' joint filing arrangement.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Millennium Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:08/07/2025
Millennium Group Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:08/07/2025
Israel A. Englander
Signature:/s/ Israel A. Englander
Name/Title:Israel A. Englander
Date:08/07/2025
Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of August 7, 2025, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

FAQ

How many Chemours (CC) shares did Millennium report owning?

7,576,095 shares, representing 5.1% of the outstanding common stock as reported on the Schedule 13G/A.

When did the reporting persons cease to be beneficial owners of more than 5% of CC?

July 1, 2025 is the date the filing states they ceased to be beneficial owners of more than 5%.

What voting and dispositive powers were reported for CC?

Shared voting power: 7,443,038; Shared dispositive power: 7,576,095; Sole voting/dispositive power: 0.

Who filed the Schedule 13G/A for Chemours (CC)?

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander are the reporting persons identified in the filing.

When was the amendment signed and who signed it?

The amendment is signed August 7, 2025; signatures include Gil Raviv (Global General Counsel) and Israel A. Englander.
Chemours Co

NYSE:CC

View CC Stock Overview

CC Rankings

CC Latest News

CC Latest SEC Filings

CC Stock Data

2.84B
148.98M
Specialty Chemicals
Chemicals & Allied Products
Link
United States
WILMINGTON